Renal dehydropeptidase-I stability of LJC 10,627, a new carbapenem antibiotic.
AUTOR(ES)
Hikida, M
RESUMO
LJC 10,627 is a new parenteral carbapenem antibiotic. LJC 10,627 stability against human renal dehydropeptidase-I was compared with that of imipenem. Hydrolysis of this compound was not detectable by spectrophotometrical assay. Even after a 2-h incubation of antibiotics with this enzyme at 30 degrees C, the concentration of LJC 10,627 remained at 92.3% of the initial concentration, whereas imipenem completely disappeared. Thus, it was found that this compound was highly stable against human renal dehydropeptidase-I. Furthermore, LJC 10,627 had a low affinity for this enzyme, as indicated by the high Ki value (0.38 mM).
ACESSO AO ARTIGO
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=188463Documentos Relacionados
- In vitro activity of LJC10,627, a new carbapenem antibiotic with high stability to dehydropeptidase I.
- In vitro and in vivo activities of LJC10,627, a new carbapenem with stability to dehydropeptidase I.
- Metabolism of Thienamycin and Related Carbapenem Antibiotics by the Renal Dipeptidase, Dehydropeptidase-I
- In vitro activity and beta-lactamase stability of LJC 10,627.
- Low neurotoxicity of LJC 10,627, a novel 1 beta-methyl carbapenem antibiotic: inhibition of gamma-aminobutyric acidA, benzodiazepine, and glycine receptor binding in relation to lack of central nervous system toxicity in rats.